Bruker BioSciences to Host Investor Booth Tour at Pittcon 2006
February 28 2006 - 6:00AM
Business Wire
Bruker BioSciences announces its annual new product booth tour for
institutional investors and analysts at Pittcon 2006 in Orlando,
Florida. The investor tour will start promptly on Tuesday, March 14
at 10 a.m. Eastern Time at the Company's booth #3155, and will last
approximately 45 minutes. To participate, please RSVP to
michael.willett@bruker-biosciences.com. Bruker BioSciences expects
to introduce a host of innovative systems and solutions for life
science and advanced materials research. Novel product
introductions will include Bruker AXS' unique QUANTAX(TM) QUAD, an
innovative EDS system for X-ray microanalysis on electron
microscopes, as well as Bruker Daltonics' novel MALDI Biotyper(TM)
system for the identification and classification of microorganisms
from protein profiles measured by MALDI-TOF mass spectrometry.
Pittcon 2006, the 57th Pittsburgh Conference and Exposition on
Analytical Chemistry and Applied Spectroscopy, is being held from
March 13-16 in Orlando, Florida in the Orange County Convention
Center. Bruker BioSciences will exhibit at booth #3155. ABOUT
BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker
AXS is a leading developer and provider of life science, materials
research and industrial X-ray analysis tools. Bruker Daltonics is a
leading developer and provider of innovative life science tools
based on mass spectrometry. For more information, please visit
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K for the year ended December 31, 2004, our most recent
quarterly reports on Form 10-Q, and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024